<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NELFINAVIR MESYLATE</span><br/>(nel-fin'a-vir)<br/><span class="topboxtradename">Viracept<br/></span><b>Classifications:</b> <span class="classification">antiinfective agent</span>; <span class="classification">antiretroviral agent</span>; <span class="classification">protease inhibitor</span><br/><b>Prototype: </b>Saquinavir<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 625 mg tablets; 50 mg/g powder</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits HIV-1 protease, which is responsible for the production of HIV-1 viral particles in an infected individual.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibition of the viral protease prevents the cleavage of the viral polypeptide, resulting in the production of an immature,
         noninfectious virus. Indicated by decreased viral load.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of HIV infection in combination with a nucleoside analog.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to nelfinavir; concurrent administration with amiodarone, quinidine, rifampin, triazolam, or midazolam; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver function impairment, hemophilia; pregnancy (category C). Safety and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 750 mg t.i.d. or 1250 mg (2 <small>x</small> 625 mg) b.i.d. with food<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>213 y,</i> 2030 mg/kg t.i.d. with food (max: 750 mg/dose)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with a meal or light snack.</li>
<li>Oral powder may be mixed with a small amount of water, milk, soy milk, or dietary supplements; liquid should be consumed immediately.
            Do not mix oral powder in original container nor with acid food or juice (e.g., orange or apple juice, or applesauce).
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Allergic reactions, back pain, fever, malaise, pain, asthenia, myalgia, arthralgia. <span class="typehead"> CNS:</span> Headache, anxiety, depression, dizziness, insomnia, seizures. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">diarrhea,</span> nausea, flatulence, anorexia, dyspepsia, <span class="speceff-life">GI bleeding</span>, hepatitis, vomiting, pancreatitis, increased liver function tests. <span class="typehead">Hematologic:</span> Anemia, leukopenia, thrombocytopenia. <span class="typehead">Respiratory:</span> Dyspnea, pharyngitis, rhinitis. <span class="typehead">Skin:</span> Rash, pruritus, sweating, urticaria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Other <span class="classification">protease inhibitors</span>, <b>ketoconazole</b> may increase nelfinavir levels; <b>rifabutin,</b>
<b>rifampin</b> may decrease nelfinavir levels; nelfinavir will decrease <span class="classification">oral contraceptive</span> levels; may increase levels of <b>atorvastatin,</b>
<b>simvastatin;</b> increase risk of <b>ergotamine</b> toxicity with <b>dihydroergotamine,</b>
<b>ergotamine.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease antiretroviral activity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Food increases the amount of drug absorbed. <span class="typehead">Distribution:</span> &gt;98% protein bound. <span class="typehead">Metabolism:</span> Metabolized in the liver by CYP3A. <span class="typehead">Elimination:</span> Primarily excreted in feces. <span class="typehead">Half-Life:</span> 3.55 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor hemophiliacs (type A or B) closely for spontaneous bleeding.</li>
<li>Monitor carefully patients with hepatic impairment for toxic drug effects.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Drug must be taken exactly as prescribed. Do not alter dose or discontinue drug without consulting physician.</li>
<li>Use a barrier contraceptive even if using hormonal contraceptives.</li>
<li>Be aware that diarrhea is a common adverse effect that can usually be controlled by OTC medications.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>